Back to Results

OrganiGram Holdings Inc (OGI)

OrganiGram Holdings Inc (OGI) is a NASDAQ-listed common stock security in the healthcare sector and pharmaceuticals industry. The instrument represents common equity in the issuing company, so it is a share class rather than a fund, note, or other special security. The underlying business is associated with cannabis and cannabis-related products and services for regulated markets, with activity that can include cultivation, processing, product formulation, and distribution. This overview reflects the listed equity and its security context, while keeping the description broad and focused on the nature of the instrument rather than any specific operating claims or market results.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-OGI
$1.27
14.3% Upside
Fair
Not available
Not available
Great
0.0%
December 22, 2026
2.6x
0.5x
0.7x
157.4 M
206.3 M
9.8%
69.0%
4.3
-34.2%
Valuation • Fair Value

OrganiGram Holdings Inc (NASDAQ-OGI) Fair Value by Valuation Model

Review the available estimates for OrganiGram Holdings Inc (NASDAQ-OGI), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.27

Estimated upside of 14.3% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.46

Discounted cash flow valuation reference.

Ben Graham Formula Value

$4.86

Classic Ben Graham valuation formula reference.

EPV Fair Value

$0.83

Earnings power value estimate.

Comps Fair Value

$1.28

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for OrganiGram Holdings Inc (NASDAQ-OGI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for OrganiGram Holdings Inc (NASDAQ-OGI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

218 M

Current operating scale indicator.

Revenue Forecast

248.8 M

Forward revenue estimate.

EBITDA

11.582 M

Current operating profitability reference.

EBITDA Forecast

25.381 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review OrganiGram Holdings Inc (NASDAQ-OGI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for OrganiGram Holdings Inc (NASDAQ-OGI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-1.04

Higher caution zone on this screen.

Altman Z-Score

4.3

Relatively strong balance-sheet zone.

FCF / Net Income

-34.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for OrganiGram Holdings Inc (NASDAQ-OGI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for OrganiGram Holdings Inc (NASDAQ-OGI)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 22, 2026

Days to Earnings

91

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for OrganiGram Holdings Inc (NASDAQ-OGI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

OrganiGram Holdings Inc (NASDAQ-OGI) Stock Forecast & Technical Outlook

Review OrganiGram Holdings Inc (NASDAQ-OGI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for OrganiGram Holdings Inc (NASDAQ-OGI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for OrganiGram Holdings Inc (NASDAQ-OGI) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for OrganiGram Holdings Inc (NASDAQ-OGI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for OrganiGram Holdings Inc (NASDAQ-OGI) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for OrganiGram Holdings Inc (NASDAQ-OGI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for OrganiGram Holdings Inc (NASDAQ-OGI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, OrganiGram Holdings Inc (NASDAQ-OGI) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ • Fast Investor Answers

OrganiGram Holdings Inc (NASDAQ-OGI) Stock FAQ

Data-supported answers about OrganiGram Holdings Inc (NASDAQ-OGI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.27
Estimated upside 14.3%
Valuation Rating
Undervalued
Estimated upside of 14.3%
Financial Health
Great
Current financial-health read

The current fair value estimate for OrganiGram Holdings Inc (NASDAQ-OGI) is $1.27. This implies an estimated upside of 14.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 14.3% versus the current market price.

The current financial health read for OrganiGram Holdings Inc (NASDAQ-OGI) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for OrganiGram Holdings Inc (NASDAQ-OGI) is December 22, 2026.

The latest available data indicates no current dividend yield for OrganiGram Holdings Inc (NASDAQ-OGI).

The current P/E ratio listed for OrganiGram Holdings Inc (NASDAQ-OGI) is 2.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for OrganiGram Holdings Inc is 157.4 M.

The current enterprise value listed for OrganiGram Holdings Inc is 206.3 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for OrganiGram Holdings Inc is NASDAQ-OGI, and the stock is listed on NASDAQ.

OrganiGram Holdings Inc (NASDAQ-OGI) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for OrganiGram Holdings Inc is 9.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for OrganiGram Holdings Inc is 69.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B